Peptides studied for sexual desire, arousal and the hormones behind them
Sexual function rests on three systems: the brain signalling that drives desire, the blood-flow pathway behind physical arousal, and the sex hormones underneath both. The compounds here act on two of these — brain arousal circuits and the hormone axis that produces testosterone. None acts directly on the blood-flow pathway.
1The biology of this goal
Sexual desire starts in the brain. Chemical messengers, including one called dopamine, switch on circuits that create the feeling of wanting sex. A separate physical step involves blood flow, which produces arousal in the genitals. Underneath both sits a chain of hormones: the brain tells the pituitary gland to signal the testes or ovaries, which then make sex hormones like testosterone. Problems with desire, arousal or function can come from any of these three layers.
Human trials, including the pivotal RECONNECT Phase 3 program, report improvements in sexual desire and reduced distress in premenopausal women with hypoactive sexual desire disorder.
Bremelanotide is a lab-made copy of a natural hormone (alpha-MSH) that acts in the brain rather than on blood vessels. It switches on melanocortin receptors in the hypothalamus, tuning circuits involved in sexual desire, and is thought to work partly through dopamine-related pathways. It is used to address low sexual desire in premenopausal women.
In premenopausal women with hypoactive sexual desire disorder, bremelanotide 1.75 mg subcutaneously significantly improved sexual desire and reduced distress compared with placebo.3
For pooled 1.25/1.75-mg doses versus placebo, mean change was +0.7 versus +0.2 satisfying sexual events per month, +3.6 versus +1.9 on the Female Sexual Function Index total score, and -11.1 versus -6.8 on the Female Sexual Distress Scale.2
Reported desire-domain score changes were modest and statistically significant (for example +0.30 in Study 301 and +0.42 in Study 302, p<.001).3
A 52-week open-label extension reported a favourable safety profile and sustained improvement, with common adverse events including nausea (40.4%), flushing (20.6%) and headache (12.0%).1
What this doesn't establish
The trials studied only premenopausal women with hypoactive sexual desire disorder; effect sizes were modest and the evidence does not establish benefit for men or for the blood-flow side of arousal.
Human trials in men with erectile dysfunction report that melanotan II initiates erections and increases sexual desire, and community and reference sources describe the same arousal effect.
Melanotan II is a lab-made, ring-shaped copy of the natural hormone alpha-MSH. It switches on melanocortin receptors that also sit in the brain, and through them it can trigger erections and increase sexual desire. It is best known for its skin-tanning effect, which cannot be separated from these other actions because it hits several receptors at once.
In the absence of sexual stimulation, melanotan II led to penile erection in 17 of 20 men with erectile dysfunction, and it was described as a potent initiator of erection.4
Increased sexual desire was reported after 68% of melanotan II doses versus 19% of placebo doses (P<0.01).4
In a double-blind crossover study of men with psychogenic erectile dysfunction, 8 of 10 achieved erections and mean tip rigidity duration was 38.0 minutes versus 3.0 minutes on placebo (p=0.0045), with no significant change in testosterone.5
Reference sources note the sexual effects are thought to relate to MC4R activation, and that alpha-MSH was shown to cause sexual arousal in rats as early as the 1960s.6
What this doesn't establish
The human trials were small, short and conducted only in men with erectile dysfunction, with frequent nausea; they do not establish safety or benefit for broader use, and melanotan II is not an approved medicine.
Regulatory and clinical sources report that HCG stimulates testosterone and sperm production, while practitioner commentary describes its use to raise endogenous testosterone.
HCG is a hormone normally made during pregnancy that closely mimics the body's own luteinizing hormone (LH). It plugs into the LH receptor on the testes and tells them to make testosterone and sperm. Because testosterone underpins libido, it is used where low hormone output is the problem.
HCG helps produce testosterone and sperm and may be used to treat low sperm count by prompting the body to make more of both.7
Regulatory prescribing information states HCG stimulates the Leydig cells of the testes to produce androgen, driving development of secondary sex characteristics.9
Practitioner commentary describes HCG raising endogenous testosterone with peak onset at 72–96 hours, notes it is unlikely to help when LH is already elevated above 20 IU/L, and warns it can raise estradiol through aromatase conversion.8
What this doesn't establish
The evidence concerns hormone and fertility endpoints, not libido or sexual function directly, and practitioner claims about testosterone effects are lower-tier; HCG does not act on brain arousal circuits or the blood-flow pathway.
Human data report that kisspeptin-10 raises FSH, LH and testosterone, while animal and laboratory studies suggest broader, sex-dependent metabolic effects.
Kisspeptin-10 is a short fragment of a natural hormone that sits at the very top of the reproductive hormone chain. It switches on the brain neurons that release GnRH, which then prompts the pituitary to release LH and FSH, which in turn drive testosterone production. In effect it kick-starts the whole hormone cascade.
Kisspeptin-10 is capable of increasing circulating follicle-stimulating hormone, luteinizing hormone and testosterone levels in humans — an effect strong enough that it is on the 2024 World Anti-Doping Agency Prohibited List.10
Its metabolic effects show significant sexual dimorphism, with increased metabolic activity and reduced body weight in females and weight gain in males.11
Practitioner reference describes LH driving Leydig-cell testosterone production, with a testosterone rise in responsive men over the following 2–8 hours, and use investigated alongside testosterone replacement therapy.12
What this doesn't establish
The evidence establishes hormone-axis stimulation, not any direct effect on libido, arousal or sexual function; it is not approved for any indication and downstream testosterone-timing figures come from lower-tier sources.
Human and mechanistic sources confirm GnRH's central role in the reproductive axis, while practitioner and community reports describe its use to maintain testosterone, fertility and libido.
Gonadorelin is a lab-made copy of the body's own GnRH, the master hormone that tells the pituitary to release LH and FSH, which then drive the testes and ovaries. Timing matters: pulses keep the system working, while continuous dosing shuts it down. It is used to keep the natural hormone signal active, including in men on testosterone therapy.
GnRH plays the central role in the hypothalamic-pituitary-gonadal axis that controls reproductive hormone output.14
Practitioner sources describe gonadorelin maintaining intratesticular testosterone and sperm production and being widely used alongside testosterone replacement therapy to preserve testicular size and endogenous production.13
Among community reports, libido was the most frequently reported benefit (181 reports).13
What this doesn't establish
The direct sexual-function claims, including libido reports, come from lower-tier community and practitioner sources rather than controlled trials in this goal; gonadorelin acts only on the hormone axis, not brain arousal circuits or blood flow.
Bremelanotide and melanotan II work through the same melanocortin receptors — bremelanotide is essentially the active fragment of melanotan II — so combining them is redundant rather than additive and simply compounds shared side effects such as nausea, flushing and over-activation; they are best not stacked. On the hormone side, HCG, gonadorelin and kisspeptin-10 all raise sex steroids but enter the axis at different levels: kisspeptin-10 acts furthest upstream on GnRH neurons, gonadorelin is GnRH acting on the pituitary, and HCG bypasses the pituitary to fire the gonadal LH receptor directly. Because they converge on the same endpoint, pairing them tends to be more redundant than synergistic and warrants hormone monitoring; in particular HCG's direct gonadal drive and negative feedback can blunt the pituitary output gonadorelin or kisspeptin-10 are meant to restore. There is no documented interaction data between the melanocortin compounds and any of the hormone-axis compounds, which is an absence of evidence rather than a clearance.
Bremelanotide + Melanotan II
Redundant — research doesn't support combining these
Both are synthetic melanocortin agonists that switch on MC4R/MC3R and route through the same cAMP signaling and central dopaminergic arousal circuits — in fact bremelanotide is essentially the active fragment of melanotan II. Stacking them is redundant, not additive, and you would simply be doubling up on the same receptor activation. It also compounds the shared side effects (nausea, flushing, blood-pressure changes, and priapism-type over-activation), so combining them raises risk without new benefit.
Not fully established
The mechanism descriptions clearly establish that both peptides are synthetic melanocortin agonists sharing multiple overlapping targets (MC4R and MC3R are explicitly listed for both), activate the same cAMP-PKA signaling cascade, and both modulate central dopaminergic pathways for sexual arousal. Both are tagged with dopaminergic_system, dopaminergic_arousal, and cAMP_PKA. The proposed relationship correctly identifies these shared mechanistic dimensions. The claim that bremelanotide is 'essentially the active fragment of melanotan II' is supported by the descriptions noting both are synthetic versions of alpha-MSH with overlapping receptor profiles. The mechanistic basis for redundancy (shared receptor activation and signaling pathways) is clearly justified by the provided material.
HCG + Gonadorelin
Worth caution — see why below
These act at different levels of the same axis: gonadorelin stimulates the pituitary to make endogenous LH/FSH, while HCG bypasses the pituitary and directly stimulates the gonadal LH receptor to drive testosterone/steroidogenesis. In principle they converge on raising sex steroids by distinct routes. However, HCG's direct gonadal drive and negative feedback can blunt the endogenous pituitary output gonadorelin is trying to restore, so pairing them requires understanding the goal (restoring the natural pituitary signal vs. directly firing the testes) and monitoring.
Not fully established
The mechanism descriptions clearly establish that both peptides operate on the testosterone_axis but at different levels: Gonadorelin acts upstream at the pituitary (stimulating LH/FSH release via GnRH-R), while HCG acts downstream at the gonad (directly stimulating LHCGR to drive steroidogenesis). Both ultimately increase sex steroids but through distinct routes—this is the definition of complementary action on a shared axis. The explanation's caveat about negative feedback and monitoring is a clinical consideration that does not contradict the complementary relationship itself. The mechanisms fully support this characterization.
HCG + Kisspeptin-10
Worth caution — see why below
Kisspeptin-10 works one step further upstream than gonadorelin \it triggers GnRH neurons, which release GnRH, which drives pituitary LH/FSH, which stimulate the gonads. HCG bypasses all of that and directly activates the gonadal LH receptor. Both ultimately raise gonadal sex hormones, so they target the same physiological endpoint by different routes. Stacking is more redundant than synergistic and warrants hormone monitoring.
Not fully established
Both peptides' mechanisms clearly converge on the testosterone_axis endpoint despite different routes. HCG directly activates LHCGR on gonads to stimulate steroidogenesis (testosterone/androgens in males). Kisspeptin-10 stimulates GnRH release → pituitary LH/FSH secretion → gonadal LH receptor activation → steroidogenesis. The mechanisms establish they share a downstream physiological endpoint (gonadal sex hormone production) via different upstream pathways, which is precisely what 'same_downstream' describes. The explanation accurately reflects the mechanistic hierarchy and the redundancy at the gonadal level is supported by both descriptions.
Gonadorelin + Kisspeptin-10
Worth caution — see why below
Kisspeptin-10 acts one step upstream, telling the hypothalamus's GnRH neurons to release their own GnRH, whereas gonadorelin IS GnRH acting directly on the pituitary. Both funnel into the same output — LH and FSH secretion and the resulting rise in sex steroids. Because they converge on the same HPG endpoint, combining them is largely redundant rather than additive, and both share the receptor desensitization risk if pulsatility isn't preserved.
Not fully established
The mechanism descriptions clearly establish that both peptides converge on the same downstream HPG axis endpoint. Gonadorelin directly targets GnRH-R on pituitary gonadotrophs to stimulate LH/FSH secretion and sex steroid increases. Kisspeptin-10 targets KISS1R on hypothalamic GnRH neurons, stimulating GnRH release, which then acts on the same pituitary GnRH-R to produce LH/FSH secretion and testosterone increases. Both are explicitly tagged 'testosterone_axis' and both mechanisms describe the same final output: LH/FSH secretion leading to sex steroid elevation. The explanation correctly identifies kisspeptin-10 as one step upstream (hypothalamic GnRH neuron stimulation) versus gonadorelin's direct pituitary action, yet both converge on identical downstream effects. The redundancy concern and receptor desensitization risk with continuous exposure are also supported by the mechanisms (gonadorelin shows 'receptor downregulation and gonadotropin suppression with continuous exposure'). This is a valid same_downstream relationship.
Bremelanotide + HCG
No documented interaction in our data — that is not a safety clearance.
Bremelanotide + Gonadorelin
No documented interaction in our data — that is not a safety clearance.
Bremelanotide + Kisspeptin-10
No documented interaction in our data — that is not a safety clearance.
Melanotan II + HCG
No documented interaction in our data — that is not a safety clearance.
Melanotan II + Gonadorelin
No documented interaction in our data — that is not a safety clearance.
Melanotan II + Kisspeptin-10
No documented interaction in our data — that is not a safety clearance.
4Compounds we looked at and left out
These share some biology with this goal, so you may have seen them recommended for it. Here is what our own research says about each.
Triptorelin is linked to testosterone axis, but in this compound that activity is about treating hormone-driven cancer and pausing puberty.
“This sustained shutdown drops testosterone in men to levels seen after surgical castration, and lowers estrogen in women, which is useful when a cancer or condition is fueled by sex hormones or when puberty needs to be paused.”— from its own profile
5What we can't tell you yet
This library has no compound linked to the nitric oxide pathway — the blood-flow mechanism behind physical arousal and erection — so it cannot speak to that side of sexual function. The strongest human trials here are limited to specific populations (premenopausal women with low desire for bremelanotide; men with erectile dysfunction for melanotan II), and the hormone-axis compounds are documented mainly for hormone and fertility endpoints rather than libido or sexual function directly.
No compound in our library is currently linked to nitric-oxide pathway.
This brief reports what published research says about these compounds. It is information, not medical advice, and not a recommendation to use anything described here. Evidence quality varies by compound and is labelled throughout. Talk to a qualified clinician before acting on any of it.